CRWD--->$231
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an alternative browser.
You should upgrade or use an alternative browser.
GBA PRESENTS- the public games
- Thread starter stonedinvestor
- Start date
NVDA $99?
NVDA $99?
Why can’t we sell puts in AH?
Lizard God called the Tech collapse, how does he do it?
Naaaa. I called a bottom on B1's thread earlier at 454 on the Q's. I think it's gonna hold.NVDA $99?
I hope so! AMD saved Tech?Naaaa. I called a bottom on B1's thread earlier at 454 on the Q's. I think it's gonna hold.
Lizard God called the Tech collapse, how does he do it?
He has very good ability to realize when people get too bullish on TV. And somehow that translates to the real market. Stupid humans always make the same mistake.
Get ready for a round of " This Is Good. "
Be careful here folks---
Arista Networks, Inc.(ANET)-
I know a bunch of hedgies in this name there was a constant drumbeat of analyst love and inside whispers... and this price reaction it just isn't enough. The chart looks pretty bad. This could easily turn over despite the good earn.
311.42-9.13(-2.85%)
At close: 4:00 PM EDT
318.00+6.58(+2.11%)<-- not enough
After hours: 5:30 PM EDT
Arista Networks, Inc.(ANET)-
I know a bunch of hedgies in this name there was a constant drumbeat of analyst love and inside whispers... and this price reaction it just isn't enough. The chart looks pretty bad. This could easily turn over despite the good earn.
311.42-9.13(-2.85%)
At close: 4:00 PM EDT
318.00+6.58(+2.11%)<-- not enough
After hours: 5:30 PM EDT
You haven't head the term rolling correction in a long while have you? I can see tomorrow setting us up for that. Lets say NVDA is not greeted well and has a massive sell off. tech has a cataclysmic day. That could be it for tech. Flatline for a month or two.
The Fed what do they want? Stock wise I would argue they want lower prices for stocks as a way of aiding in keeping the economy down.
The way they can jawbone stocks down is by not putting Sept firmly on the table. By not doing that small caps will retreat big time. I have not bought this " rotation " talk but it is being sold hard on the street. It just doesn't feel that way to me.
There was a flight to safety in bonds today not to be ignored. ~stoney
The Fed what do they want? Stock wise I would argue they want lower prices for stocks as a way of aiding in keeping the economy down.
The way they can jawbone stocks down is by not putting Sept firmly on the table. By not doing that small caps will retreat big time. I have not bought this " rotation " talk but it is being sold hard on the street. It just doesn't feel that way to me.
There was a flight to safety in bonds today not to be ignored. ~stoney
Biotech King, any of these catch your fancy?
“Neuron IMNN Phase 2 Topline Data; CNS Pharmaceuticals CNSP License Deal - Pre-Market Updates • BioPharmCatalyst
IMUNON, Inc. (NASDAQ: IMNN) announced the topline results from the Phase 2 OVATION 2 Study with IMNN-001 in patients with advanced ovarian cancer. Data reported a three-month improvement in PFS compared with standard-of-care alone, and an 11.1 month increase in median OS.
CNS Pharmaceuticals (NASDAQ: CNSP) entered into an exclusive license agreement with Cortice Biosciences for TPI 287, a potential blood-brain barrier permeable microtubule inhibitor for glioblastoma multiforme (GBM) treatment. CNS plans to engage with the FDA to design a potential registration study for TPI 287 in recurrent GBM, aiming to start in 2025.
Cognition Therapeutics (NASDAQ: CGTX) reported results from their Phase 2 study of CT1812 (SHINE) for treating Alzheimer’s disease. The drug showed a consistent trend in cognitive improvement compared to placebo across multiple measures. However, CT1812 did not achieve statistical significance on the first-ordered secondary efficacy endpoint.
Fractyl Health (NASDAQ: GUTS) announced that the FDA has granted Breakthrough Device Designation for their Revita System, designed to maintain weight loss after discontinuation of GLP-1 drugs. Revita is an outpatient endoscopic procedure that resurfaces the duodenal lining to potentially address a root cause of obesity and type 2 diabetes. Fractyl expects to report data from an open-label study in weight maintenance in Q4 2024 and a mid-point randomized analysis of the REMAIN-1 pivotal study in Q2 2025.
Evoke Pharma, Inc. (NASDAQ: EVOK) announced a 1-for-12 reverse stock split of the company’s common stock. The reverse stock split will become effective at 12:01 a.m. ET on August 1, 2024.
T2 Biosystems (NASDAQ: TTOO) reported second quarter 2024 results, with losses of $0.66 per share beating estimates by $0.31, but revenue of $1.95 million missing by $0.15 million or 7.05% below expectations. Canaccord Genuity maintained a Hold rating and raised the price target from $3 to $5.
Day One Biopharmaceuticals, Inc.(NASDAQ: DAWN) announced it has entered into a securities purchase agreement for an oversubscribed private placement of its securities for gross proceeds of approximately $175.0 million, before deducting placement agent fees and other expenses.
Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced the authorization of its Clinical Trial Application (CTA) by the United Kingdom’s Medicine and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 1/2 study evaluating NTLA-3001 for the treatment of alpha-1 antitrypsin deficiency (AATD)-associated lung disease. The trial is on track to dose the first patient in 2H 2024.”
https://www.biopharmcatalyst.com/
“Neuron IMNN Phase 2 Topline Data; CNS Pharmaceuticals CNSP License Deal - Pre-Market Updates • BioPharmCatalyst
IMUNON, Inc. (NASDAQ: IMNN) announced the topline results from the Phase 2 OVATION 2 Study with IMNN-001 in patients with advanced ovarian cancer. Data reported a three-month improvement in PFS compared with standard-of-care alone, and an 11.1 month increase in median OS.
CNS Pharmaceuticals (NASDAQ: CNSP) entered into an exclusive license agreement with Cortice Biosciences for TPI 287, a potential blood-brain barrier permeable microtubule inhibitor for glioblastoma multiforme (GBM) treatment. CNS plans to engage with the FDA to design a potential registration study for TPI 287 in recurrent GBM, aiming to start in 2025.
Cognition Therapeutics (NASDAQ: CGTX) reported results from their Phase 2 study of CT1812 (SHINE) for treating Alzheimer’s disease. The drug showed a consistent trend in cognitive improvement compared to placebo across multiple measures. However, CT1812 did not achieve statistical significance on the first-ordered secondary efficacy endpoint.
Fractyl Health (NASDAQ: GUTS) announced that the FDA has granted Breakthrough Device Designation for their Revita System, designed to maintain weight loss after discontinuation of GLP-1 drugs. Revita is an outpatient endoscopic procedure that resurfaces the duodenal lining to potentially address a root cause of obesity and type 2 diabetes. Fractyl expects to report data from an open-label study in weight maintenance in Q4 2024 and a mid-point randomized analysis of the REMAIN-1 pivotal study in Q2 2025.
Evoke Pharma, Inc. (NASDAQ: EVOK) announced a 1-for-12 reverse stock split of the company’s common stock. The reverse stock split will become effective at 12:01 a.m. ET on August 1, 2024.
T2 Biosystems (NASDAQ: TTOO) reported second quarter 2024 results, with losses of $0.66 per share beating estimates by $0.31, but revenue of $1.95 million missing by $0.15 million or 7.05% below expectations. Canaccord Genuity maintained a Hold rating and raised the price target from $3 to $5.
Day One Biopharmaceuticals, Inc.(NASDAQ: DAWN) announced it has entered into a securities purchase agreement for an oversubscribed private placement of its securities for gross proceeds of approximately $175.0 million, before deducting placement agent fees and other expenses.
Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced the authorization of its Clinical Trial Application (CTA) by the United Kingdom’s Medicine and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 1/2 study evaluating NTLA-3001 for the treatment of alpha-1 antitrypsin deficiency (AATD)-associated lung disease. The trial is on track to dose the first patient in 2H 2024.”
https://www.biopharmcatalyst.com/